{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:33:13Z","timestamp":1775856793682,"version":"3.50.1"},"reference-count":24,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.3892\/etm.2011.198","type":"journal-article","created":{"date-parts":[[2011,1,19]],"date-time":"2011-01-19T13:48:33Z","timestamp":1295444913000},"page":"295-299","source":"Crossref","is-referenced-by-count":2,"title":["High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma"],"prefix":"10.3892","volume":"2","author":[{"given":"J.","family":"BRUNOTTE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"BOCK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"BR\u00dcCK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"HEMMERLEIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"STRIK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2011,1,19]]},"reference":[{"key":"key20180108122718_b1-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L","article-title":"The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data","volume":"85","author":"Davis","year":"1999","journal-title":"Cancer"},{"key":"key20180108122718_b2-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180108122718_b3-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2119\/2006-00042.Erbayraktar","article-title":"Carbamylated erythropoietin reduces radiosurgically-induced brain injury","volume":"12","author":"Erbayraktar","year":"2006","journal-title":"Mol Med"},{"key":"key20180108122718_b4-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0093-7754(01)90208-8","article-title":"The erythropoietin receptor","volume":"28","author":"Mulcahy","year":"2001","journal-title":"Semin Oncol"},{"key":"key20180108122718_b5-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1271\/bbb.64.1775","article-title":"Erythropoietin: multiple physiological functions and regulation of biosynthesis","volume":"64","author":"Sasaki","year":"2000","journal-title":"Biosci Biotechnol Biochem"},{"key":"key20180108122718_b6-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/sonc.2002.34067","article-title":"Evidence for erythropoietin as a molecular targeting agent","volume":"29","author":"Leyland-Jones","year":"2002","journal-title":"Semin Oncol"},{"key":"key20180108122718_b7-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1126\/science.257.5073.1138","article-title":"A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells","volume":"257","author":"Nakamura","year":"1992","journal-title":"Science"},{"key":"key20180108122718_b8-etm-02-02-0295","first-page":"759","article-title":"Anaemia and cancer treatment: a conceptual change","volume":"49","author":"Khan","year":"2008","journal-title":"Singapore Med J"},{"key":"key20180108122718_b9-etm-02-02-0295","first-page":"39","article-title":"Erythropoietic agents in the management of cancer patients. Part 2: studies on their role in neuroprotection and neurotherapy","volume":"2","author":"Smith","year":"2004","journal-title":"J Support Oncol"},{"key":"key20180108122718_b10-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF01714953","article-title":"Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro","volume":"63","author":"Berdel","year":"1991","journal-title":"Ann Hematol"},{"key":"key20180108122718_b11-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3171\/jns.2007.106.2.338","article-title":"Survival and invasiveness of astrocytomas promoted by erythropoietin","volume":"106","author":"Mohyeldin","year":"2007","journal-title":"J Neurosurg"},{"key":"key20180108122718_b12-etm-02-02-0295","first-page":"13","article-title":"Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels","volume":"174","author":"Molls","year":"1998","journal-title":"Strahlenther Onkol"},{"key":"key20180108122718_b13-etm-02-02-0295","first-page":"4728","article-title":"Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats","volume":"56","author":"Kelleher","year":"1996","journal-title":"Cancer Res"},{"key":"key20180108122718_b14-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0360-3016(97)00101-6","article-title":"Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck","volume":"38","author":"Brizel","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108122718_b15-etm-02-02-0295","first-page":"4509","article-title":"Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix","volume":"56","author":"H\u00f6ckel","year":"1996","journal-title":"Cancer Res"},{"key":"key20180108122718_b16-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1158\/0008-5472.284.65.1","article-title":"Darbepoietin alpha potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia","volume":"65","author":"Ning","year":"2005","journal-title":"Cancer Res"},{"key":"key20180108122718_b17-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijrobp.2003.12.022","article-title":"Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts","volume":"59","author":"Pinel","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108122718_b18-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/bjc.1998.572","article-title":"Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia","volume":"78","author":"Thews","year":"1998","journal-title":"Br J Cancer"},{"key":"key20180108122718_b19-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/030089160208800214","article-title":"Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality","volume":"88","author":"Westphal","year":"2002","journal-title":"Tumori"},{"key":"key20180108122718_b20-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ijrobp.2008.06.1923","article-title":"Erythropoietin augments survival of glioma cells after radiation and temozolomide","volume":"72","author":"Hassouna","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20180108122718_b21-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2990.2006.00820.x","article-title":"De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival","volume":"33","author":"Mittelbronn","year":"2007","journal-title":"Neuropathol Appl Neurobiol"},{"key":"key20180108122718_b22-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"key20180108122718_b23-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1200\/JCO.2005.06.150","article-title":"Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study","volume":"23","author":"Leyland-Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108122718_b24-etm-02-02-0295","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djj189","article-title":"Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients","volume":"98","author":"Bohlius","year":"2006","journal-title":"J Natl Cancer Inst"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2011.198\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T22:39:43Z","timestamp":1685918383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2011.198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,1,19]]},"published-print":{"date-parts":[[2011]]}},"alternative-id":["10.3892\/etm.2011.198"],"URL":"https:\/\/doi.org\/10.3892\/etm.2011.198","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}